Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT)

Bioconjug Chem. 2006 Mar-Apr;17(2):410-8. doi: 10.1021/bc0503521.

Abstract

CC49 is a clinically validated antibody with specificity for TAG-72, a carbohydrate epitope that is overexpressed and exposed on the cell surface in a large fraction of solid malignancies. We constructed a single-chain fragment (scFv) based on CC49 and fused it to beta-lactamase (BLA). Following optimization of the scFv domain by combinatorial consensus mutagenesis (CCM) for increased expression and stability, we characterized the protein variant for binding, in vivo pharmacokinetics (PK), and antitumor efficacy. The fusion protein TAB2.5 possessed a similar binding specificity relative to the parent antibody CC49. TAB2.5 also showed prolonged retention (T(1/2) = 36.9 h) in tumor-bearing mice with tumor/plasma ratios of up to 1000. Preliminary evaluation of TAB2.5, in combination with a novel prodrug, GC-Mel, resulted in significant efficacy in a colorectal xenograft tumor model and supports the utility of the protein as an agent for tumor-selective prodrug activation.

Publication types

  • Evaluation Study

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / therapeutic use
  • Antibodies, Neoplasm* / chemistry
  • Antibodies, Neoplasm* / genetics
  • Antibodies, Neoplasm* / metabolism
  • Antibodies, Neoplasm* / therapeutic use
  • Antineoplastic Agents, Alkylating / chemistry
  • Antineoplastic Agents, Alkylating / metabolism
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Camptothecin / analogs & derivatives
  • Camptothecin / therapeutic use
  • Cephalosporins / chemistry*
  • Cephalosporins / metabolism*
  • Cephalosporins / therapeutic use*
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / metabolism
  • Colorectal Neoplasms / pathology
  • Doxorubicin / therapeutic use
  • Drug Carriers / chemistry
  • Drug Carriers / metabolism
  • Drug Delivery Systems
  • Female
  • Humans
  • Immunoglobulin Fragments / genetics
  • Immunoglobulin Fragments / metabolism
  • Immunoglobulin Variable Region / genetics
  • Immunoglobulin Variable Region / metabolism
  • Irinotecan
  • Melphalan / chemistry
  • Melphalan / metabolism
  • Melphalan / therapeutic use
  • Mice
  • Mice, Nude
  • Molecular Structure
  • Neoplasm Transplantation
  • Nitrogen Mustard Compounds / chemistry*
  • Nitrogen Mustard Compounds / metabolism*
  • Nitrogen Mustard Compounds / therapeutic use*
  • Prodrugs* / chemistry
  • Prodrugs* / metabolism
  • Prodrugs* / therapeutic use
  • Recombinant Fusion Proteins / chemistry
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / metabolism*
  • Recombinant Fusion Proteins / therapeutic use*
  • beta-Lactamases* / chemistry
  • beta-Lactamases* / genetics
  • beta-Lactamases* / metabolism
  • beta-Lactamases* / therapeutic use

Substances

  • Antibiotics, Antineoplastic
  • Antibodies, Neoplasm
  • Antineoplastic Agents, Alkylating
  • Antineoplastic Agents, Phytogenic
  • B72.3 antibody
  • Cephalosporins
  • Drug Carriers
  • Immunoglobulin Fragments
  • Immunoglobulin Variable Region
  • Nitrogen Mustard Compounds
  • Prodrugs
  • Recombinant Fusion Proteins
  • TAB2.5 fusion protein
  • glutaryl C-Mel
  • Irinotecan
  • Doxorubicin
  • beta-Lactamases
  • Melphalan
  • Camptothecin